Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of satralizumab versus placebo in moderate-to-severe thyroid eye disease
2023-503309-13-00Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in Graves Orbitopathy (GO) comparing Satralizumab with Placebo (2 arms). Primary endpoint: Proptosis responder rate in active disease at Week 24. Started Oct 2023; status: completed.
02
Drugs
satralizumab
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on 2023-503309-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503309-13-00.